A.I. Virtanen Institute for Molecular Sciences - News

The doctoral thesis studied the mechanisms between diabetes and atherosclerosis leading to cardiovascular complications.

Jane and Aatos Erkko Foundation funds a collaborative epilepsy research project between A.I.Virtanen Institute and KUH Epilepsy Center. The long term aim of the project is to improve the treatment of drug-resistant epilepsy.

Rokote Laboratories Finland Ltd. and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.

A novel angiogenic microRNA drug can be a new option for the treatment of ischemic cardiovascular disease.

Malm’s funding is the first ever ERC Consolidator Grant granted by the ERC Neuroscience panel to a Finnish researcher.

The university has opened another call for applications for Proof of Concept (PoC) funding to accelerate the commercialisation of research-based ideas. For Professor Tarja Malm, PoC projects have opened several doors.

The new cell model for Alzheimer’s disease is based on patient-derived cells of the olfactory mucosa, located in the upper parts of the nasal cavity.

Using patient-derived iPSC models, the PhD study identified several gene and protein expressional changes associated with clinical manifestation and increased risk to develop schizophrenia.

“Coronary artery disease has, for a long time, been mainly treated with cholesterol-lowering drugs, but there is a need for other types of treatments as well. For example, new drugs could target pathogenic changes taking place in the arterial wall,” Professor Minna Kaikkonen-Määttä says.